J.P. Morgan Reiterates Overweight Rating on McKesson Corporation Following Investor Day

In a report published Thursday, J.P. Morgan analyst Lisa C. Gill reiterated an Overweight rating on

. In the report, J.P. Morgan noted, “We attended McKesson's annual Investor Day in Boston today where management confirmed FY 2014 guidance of $7.90-$8.20. Additionally management noted that strong economic contributions from both generics and brands drove an unusually strong fiscal Q1 (June 30) ahead of expectations. While nothing new was presented at the Analyst Day, we continue to believe that MCK is well positioned for future growth. Furthermore, we remain confident that this management team will continue its solid track record of execution. Strong relationships across the Rx channel should enable the company to continue to expand relationships with existing accounts, driving medication adherence and the Affordable Care Act (ACA) should continue to grow volumes, and strong cash should enable future accretive uses of cash flow going forward.” McKesson Corporation closed on Wednesday at $115.54.